Application value of serum HBV RNA in clinical management of chronic hepatitis B

Liao Hao; Wang Jie; Lu FengMin

doi:10.3969/j.issn.1001-5256.2019.10.003

Volume 35 Issue 10

Oct. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(10): 2145-2149

PDF( 1908 KB)

Application value of serum HBV RNA in clinical management of chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2019.10.003

Peking University Shenzhen Hospital & Shenzhen PKU-HKUST Medical Center

Research funding:

Received Date: 2019-08-01
Published Date: 2019-10-20

Abstract

Abstract

Viral hepatitis,liver cirrhosis,and hepatocellular carcinoma caused by hepatitis B virus(HBV) infection still threaten the health of people in China. Efficient antiviral therapy can significantly prevent the progression of liver diseases and reduce the incidence rate of end-stage liver disease,but it is very difficult to achieve clinical cure by current drugs,and nucleos(t) ide analogues may require long-term medication. New serological markers can be used for further optimization of antiviral regimens,among which serum HBV RNA is transcribed from covalently closed circular DNA(cccDNA) and is mainly derived from pregenomic RNA and its splice variants with no or partial reverse transcription. This article summarizes the sources and existing forms of serum HBV RNA,the influencing factors for serum HBV RNA level,the correlation between serum HBV RNA and other serum virological markers,and the correlation between serum HBV RNA and cccDNA in liver tissue,as well as the clinical significance of serum HBV RNA in monitoring antiviral efficacy and predicting the risk of viral rebound after drug withdrawal.
- hepatitis B virus,
- RNA,
- DNA,circular,
- antiviral agents

FullText(HTML)

References(37)

References

[1] KCK J,THEILMANN L,GALLE P,et al. Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus[J]. Hepatology,1996,23(3):405-413.

[2] WANG J,SHEN T,HUANG X,et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol,2016,65(4):700-710.

[3] JANSEN L,KOOTSTRA NA,van DORT KA,et al. Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues[J]. J Infect Dis,2016,213(2):224-232.

[4] LAM AM,REN S,ESPIRITU C,et al. Hepatitis B virus capsid assembly modulators,but not nucleoside analogs,inhibit the production of extracellular pregenomic RNA and spliced RNA variants[J]. Antimicrob Agents Chemother,2017,61(8):e00680-17.

[5] PRAKASH K,RYDELL GE,LARSSON SB,et al. High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles[J]. Virol J,2018,15(1):86.

[6] BAI L,ZHANG X,KOZLOWSKI M,et al. Extracellular hepatitis B virus RNAs are heterogeneous in length and circulate as capsidantibody complexes in addition to virions in chronic hepatitis B patients[J]. J Virol,2018,92(24):e00798-18.

[7] CHEN J,WU M,WANG F,et al. Hepatitis B virus spliced variants are associated with an impaired response to interferon therapy[J]. Sci Rep,2015,5:16459.

[8] KAIRAT A,BEERHEIDE W,ZHOU G,et al. Truncated hepatitis B virus RNA in human hepatocellular carcinoma:Its representation in patients with advancing age[J]. Intervirology,1999,42(4):228-237.

[9] ZHANG P,LIU F,GUO F,et al. Characterization of novel hepadnaviral RNA species accumulated in hepatoma cells treated with viral DNA polymerase inhibitors[J]. Antiviral Res,2016,131:40-48.

[10] WANG J,SHENG Q,DING Y,et al. HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient[J]. J Hepatol,2018,68(4):847-849.

[11] BUTLER EK,GERSCH J,MCNAMARA A,et al. Hepatitis B virus serum DNA and RNA levels in nucleos(t)ide analog-treated or untreated patients during chronic and acute infection[J]. Hepatology,2018,68(6):2106-2117.

[12] WANG J,YU Y,LI G,et al. Natural history of serum HBVRNA in chronic HBV infection[J]. J Viral Hepat,2018,25(9):1038-1047.

[13] van CAMPENHOUT MJH,van BMMEL F,PFEFFERKORN M,et al. Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment[J].Hepatology,2018,68(3):839-847.

[14] HUANG H,WANG J,LI W,et al. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-nave HBV-infected individuals[J]. J Clin Virol,2018,99-100:71-78.

[15] WANG J,YU Y,LI G,et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients[J]. J Hepatol,2017,pii:S0168-8278(17)32261-4.

[16] GIERSCH K,ALLWEISS L,VOLZ T,et al. Serum HBV pgRNA as a clinical marker for cccDNA activity[J]. J Hepatol,2017,66(2):460-462.

[17] LIAO H,LIU Y,LI X,et al. Monitoring of serum HBV RNA,HBcrAg,HBs Ag and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy[J]. Antivir Ther,2019,24(2):105-115.

[18] van BMMEL F,van BMMEL A,KRAUEL A,et al. Serum HBV RNA as a predictor of peginterferon alfa-2a response in patients with HBe Ag-positive chronic hepatitis B[J]. J Infect Dis,2018,218(7):1066-1074.

[19] WANG J,DU M,HUANG H,et al. Reply to:"Serum HBV pgRNA as a clinical marker for cccDNA activity":Consistent loss of serum HBV RNA might predict the"para-functional cure"of chronic hepatitis B[J]. J Hepatol,2017,66(2):462-463.

[20] HUANG YW,TAKAHASHI S,TSUGE M,et al. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy[J]. Antivir Ther,2015,20(4):369-375.

[21] van BMMEL F,BARTENS A,MYSICKOVA A,et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors[J]. Hepatology,2015,61(1):66-76.

[22] LUO H,ZHANG XX,CAO LH,et al. Serum hepatitis B virus RNA is a predictor of HBe Ag seroconversion and virological response with entecavir treatment in chronic hepatitis B patients[J]. World J Gastroenterol,2019,25(6):719-728.

[23] HATAKEYAMA T,NOGUCHI C,HIRAGA N,et al. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine[J]. Hepatology,2007,45(5):1179-1186.

[24] GANE EJ. Future anti-HBV strategies[J]. Liver Int,2017,37(Suppl 1):40-44.

[25] SORIANO V. Hot news:Hepatitis B gene therapy coming to age[J]. AIDS Rev,2018,20(2):125-127.

[26] LAM AM,ESPIRITU C,VOGEL R,et al. Preclinical characterization of NVR 3-778,a first-in-class capsid assembly modulator against hepatitis B virus[J]. Antimicrob Agents Chemother,2019,63(1)pii:e01734-18.

[27] YUEN MF,GANE EJ,KIM DJ,et al. Antiviral activity,safety,and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection[J]. Gastroenterology,2019,156(5):1392-1403.

[28] LAHLALI T,BERKE JM,VERGAUWEN K,et al. Novel potent capsid assembly modulators regulate multiple steps of the hepatitis B virus life cycle[J]. Antimicrob Agents Chemother,2018,62(10). pii:e00835-18.

[29] SARIN SK,KUMAR M,LAU GK,et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B:A 2015update[J]. Hepatol Int,2016,10(1):1-98.

[30] European Association for the Study of the Liver. EASL 2017Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol,2017,67(2):370-398.

[31] TERRAULT NA,LOK ASF,MCMAHON BJ,et al. Update on prevention,diagnosis,and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J]. Hepatology,2018,67(4):1560-1599.

[32] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention andtreatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.

[33] TSUGE M,MURAKAMI E,IMAMURA M,et al. Serum HBV RNA and HBe Ag are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients[J]. J Gastroenterol,2013,48(10):1188-1204.

[34] WANG J,CHEN X,WU Y,et al. Serum HBV RNA is a potential predictor of hepatitis B surface antigen reversion[J]. Hepatol Commun,2018,2(10):1168-1171.

[35] LU F,WANG J,CHEN X,et al. Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs[J]. Front Med,2017,11(4):502-508.

[36] LU FM,WANG J,CHEN XM,et al. The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B[J]. Chin J Hepatol,2017,25(2):105-110.(in Chinese)鲁凤民,王杰,陈香梅,等.乙型肝炎病毒RNA病毒样颗粒的发现及其对抗病毒治疗临床实践的潜在影响[J].中华肝脏病杂志,2017,25(2):105-110.

[37] LU FM,DOU XG,ZHANG WH,et al. Clinical significance of serum HBV RNA measurement in chronic hepatitis B patients[J]. J Clin Hepatol,2018,34(5):934-938.(in Chinese)鲁凤民,窦晓光,张文宏,等.慢性乙型肝炎患者血清HBV RNA检测的临床意义[J].临床肝胆病杂志,2018,34(5):934-938.

Relative Articles

[1]	Chaoran YANG, Sirou LI, Yuan LIU, Zhiyuan HOU, Yuan WANG, Jihong YANG. Role of non-coding RNA on immune cells in tumor microenvironment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(4): 961-967. doi: 10.3969/j.issn.1001-5256.2023.04.033
[2]	Yao GAO, Feng REN, Zhongping DUAN. Current research status of hepatitis D virus RNA detection[J]. Journal of Clinical Hepatology, 2023, 39(4): 758-765. doi: 10.3969/j.issn.1001-5256.2023.04.004
[3]	Lixian WU, Weiqiang ZHENG, Huanqin HAN. Effect of different antiviral drugs in reducing the risk of hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 1165-1168. doi: 10.3969/j.issn.1001-5256.2022.05.040
[4]	Mingyang FENG, Hui WANG. Selection of antiviral drugs for patients with hepatitis B virus-associated hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2452-2456. doi: 10.3969/j.issn.1001-5256.2022.11.004
[5]	Baolin XU, Yu CHENG, Yong WEI. The role of competitive endogenous RNA in the development of cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2659-2662. doi: 10.3969/j.issn.1001-5256.2022.11.044
[6]	Yang WANG, Hao LIAO, Zhongping DENG, Dandan BIAN, Yan REN, Yingying JIANG, Shuang LIU, Yu CHEN, Fengmin LU, Zhongping DUAN, Sujun ZHENG. Comparison of two quantitative real-time PCR methods for serum HBV RNA in patients with HBeAg-positive chronic hepatitis B: A propensity score matching study[J]. Journal of Clinical Hepatology, 2022, 38(5): 1035-1040. doi: 10.3969/j.issn.1001-5256.2022.05.012
[7]	Hui ZHUANG. Are there only a few steps away from the prime time for hepatitis B virus RNA as a routine marker to guide decision making in treatment of chronic hepatitis B?[J]. Journal of Clinical Hepatology, 2022, 38(2): 285-287. doi: 10.3969/j.issn.1001-5256.2022.02.008
[8]	Jing LI, Yu CAO, Yongmei FENG, Yuanqiang GUO, Bei JIANG, Chunyan WANG. HBV RNA level in patients with HBV-related hepatocellular carcinoma after long-term antiviral therapy with nucleos(t)ide analogues and its clinical significance[J]. Journal of Clinical Hepatology, 2021, 37(10): 2324-2326. doi: 10.3969/j.issn.1001-5256.2021.10.013
[9]	Zai WenJing, Chen JieLiang, Yuan ZhengHong. Regulatory mechanisms of the transcription and metabolism of hepatitis B virus covalently closed circular DNA and strategies for silencing and elimination[J]. Journal of Clinical Hepatology, 2020, 36(5): 983-988. doi: 10.3969/j.issn.1001-5256.2020.05.006
[10]	Wang Ying, Zhao Kui, Qin JianZhong. Value of combined measurement of hepatitis B virus covalently closed circular DNA,HBsAg,and hepatitis B virus pregenomic RNA in predicting the treatment outcome of HBeAg-positive chronic hepatitis B patients treated with entecavir[J]. Journal of Clinical Hepatology, 2020, 36(5): 1008-1013. doi: 10.3969/j.issn.1001-5256.2020.05.012
[11]	Zhang Yu, Zhao JingMin. Clinical application of covalently closed circular DNA detection techniques[J]. Journal of Clinical Hepatology, 2019, 35(10): 2140-2144. doi: 10.3969/j.issn.1001-5256.2019.10.002
[12]	Lei GuangLin, Wang Quan, Cheng SiJie, Lai ChengCai, Wang KeYu, Yan Jin, Yang PengHui, Zhang ShaoGeng. Expression of the long non-coding RNA XLOC-007123 in hepatitis B-related hepatocellular carcinoma and its clinical significance[J]. Journal of Clinical Hepatology, 2018, 34(2): 309-313. doi: 10.3969/j.issn.1001-5256.2018.02.018
[13]	Lu FengMin, Dou XiaoGuang, Zhang WenHong, Wang FuSheng. Clinical significance of serum HBV RNA measurement in chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2018, 34(5): 934-938. doi: 10.3969/j.issn.1001-5256.2018.05.005
[14]	Chen Wei, Wu Feng, Dou XiaoGuang, Zhang Lin. Analysis of related factors for intrahepatic HBV cccDNA level in patients with chronic HBV infection[J]. Journal of Clinical Hepatology, 2013, 29(6): 434-437.
[15]	Zhang LiLi, Guo XiaoHong, Liu LiXin, Zhang QianQian. IGFBPrP1 siRNA induced apoptosis in rat hepatic stellate cells and its mechanism[J]. Journal of Clinical Hepatology, 2011, 27(9): 965-969+979.
[16]	Liu LiXin, Qiu ZhiHong, Zhang QianQian. Effects of knocking down IGFBPrP1 with siRNA on extracellular matrix secretion in HSC-T6[J]. Journal of Clinical Hepatology, 2011, 27(3): 248-250.
[17]	Xu ChunHai, Li ZhaoShen, Dai JunYing, Zhu HaiYang, Yu JianWu, Lu: ShuLan. Establishment and application of nested real-time fluorescent quantitative polymerase chain reaction assay for detection of hepatitis B virus covalently closed circular DNA[J]. Journal of Clinical Hepatology, 2011, 27(3): 283-285+291.
[18]	Chen Peng, Zheng SuJun, Wang ShiMei, Zhang JianJun, Xing XinYue, Zhang Ying, Liu Mei, Duan ZhongPing. Selection of siRNA and construction of recombinant lentivirus expressing shRNA targeting rat Smad3 gene[J]. Journal of Clinical Hepatology, 2011, 27(5): 533-537.
[19]	Su MingHua, Jiang JianNing, Zhou YuanPing, Chen MaoWei, Liu ZhiHong. Study of the relationship between BCP mutation in the hepatitis B virus gene and HBVDNA rebound after lamivudine therapy[J]. Journal of Clinical Hepatology, 2008, 24(3): 172-174.

Supplements(0)

Cited By

Cited by

Periodical cited type(8)

1.	吴宝灵，徐龙，余海滨，徐贞秋，吴敏，张伟，范声春，李艳艳，李金明. 血清HBsAg、HBV RNA水平对慢性乙型肝炎患者核苷(酸)类药物治疗停药预测的价值. 实用临床医学. 2023(05): 1-4 .
2.	高林，毛天皓，彭思雯，王杰，陈香梅，鲁凤民. 核苷(酸)治疗下较短的cccDNA半衰期或给"乙肝治愈"点燃希望. 中华肝脏病杂志. 2022(01): 99-102 .
3.	孙华宝，李美琦，赖启南，斯志娟，漆童丰，王淑梅. 血清HBV RNA定量检测在慢性乙肝患者抗病毒治疗中临床研究. 实验与检验医学. 2022(03): 306-309 .
4.	李小鹏，李雷，袁松松，王亮，何颖，黄建生，邬小萍. 高灵敏乙型肝炎病毒DNA阴性慢性乙型肝炎患者70例血清乙型肝炎病毒前基因组RNA水平的分析. 中华传染病杂志. 2021(09): 558-561 .
5.	刘明琛，杨兴雯，鲁凤民. 新发现, 大用途——慢性乙型肝炎患者血清HBV RNA检测的应用. 中国生物化学与分子生物学报. 2020(08): 865-871 .
6.	鲁凤民，王杰，陈香梅，张欣欣，张文宏，徐小元，贾继东，任红. 新型血清指标在乙型肝炎创新药物研发中的应用. 中华肝脏病杂志. 2020(08): 649-653 .
7.	朱旭庆，尹春煜. 核苷(酸)类药物抗乙型肝炎病毒治疗停药相关研究进展. 中西医结合肝病杂志. 2020(06): 571-573 .
8.	卢惠萍. 核苷（酸）类似物抗病毒药对HBV感染病毒学复发的影响. 中国卫生标准管理. 2020(23): 1-3 .

Other cited types(6)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2566) PDF downloads(502)

Application value of serum HBV RNA in clinical management of chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2019.10.003